Complete pathologic response of HER2-positive breast cancer liver metastasis with dual Anti-HER2 antagonism

被引：0
|
作者：
Hans F Schoellhammer
Felicia Hsu
Courtney Vito
Peiguo Chu
Jinha Park
James Waisman
Joseph Kim
机构：
[1] City of Hope Comprehensive Cancer Center,Division of Surgical Oncology, Department of Surgery
[2] City of Hope Comprehensive Cancer Center,Department of Pathology
[3] City of Hope Comprehensive Cancer Center,Department of Radiology
[4] City of Hope Comprehensive Cancer Center,Department of Medical Oncology and Experimental Therapeutics Research
来源：
BMC Cancer | / 14卷
关键词：
HER2-positive breast cancer; Targeted therapy; Breast cancer liver metastases; Trastuzumab; Pertuzumab; Complete pathologic response;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Anti-HER2 antibody therapy using gene-transduced adipocytes for HER2-positive breast cancer
    Takahito Masuda
    Hiroshi Fujimoto
    Ryotaro Teranaka
    Masayuki Kuroda
    Yasuyuki Aoyagi
    Takeshi Nagashima
    Takafumi Sangai
    Mamoru Takada
    Ayako Nakagawa
    Yoshitaka Kubota
    Koutaro Yokote
    Masayuki Ohtsuka
    Breast Cancer Research and Treatment, 2020, 180 : 625 - 634
  • [32] Pathologic Complete Response in HER2-Positive Breast Cancer Patients Receiving Trastuzumab in Neoadjuvant Setting
    Sheikh, Fareeha
    Nazir, Adil
    Yasmeen, Samia
    Badar, Farhana
    Ahmad, Usman
    Siddiqui, Neelam
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2019, 29 (02): : 159 - 163
  • [33] Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial
    de Azambuja, E.
    Agostinetto, E.
    Procter, M.
    Eiger, D.
    Ponde, N.
    Guillaume, S.
    Parlier, D.
    Lambertini, M.
    Desmet, A.
    Caballero, C.
    Aguila, C.
    Jerusalem, G.
    Walshe, J. M.
    Frank, E.
    Bines, J.
    Loibl, S.
    Piccart-Gebhart, M.
    Ewer, M. S.
    Dent, S.
    Plummer, C.
    Suter, T.
    ESMO OPEN, 2023, 8 (01)
  • [34] Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer
    Lin, Binwei
    Fan, Jinjia
    Liu, Fang
    Wen, Yixue
    Li, Jie
    Gao, Feng
    Zhang, Yu
    Feng, Gang
    Du, Xiaobo
    Chen, Wenzhi
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2023, 22
  • [35] MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy
    Mette S. van Ramshorst
    Claudette E. Loo
    Emilie J. Groen
    Gonneke H. Winter-Warnars
    Jelle Wesseling
    Frederieke van Duijnhoven
    Marie-Jeanne T. Vrancken Peeters
    Gabe S. Sonke
    Breast Cancer Research and Treatment, 2017, 164 : 99 - 106
  • [36] Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer
    Lin, Binwei
    Fan, Jinjia
    Liu, Fang
    Wen, Yixue
    Li, Jie
    Gao, Feng
    Zhang, Yu
    Feng, Gang
    Du, Xiaobo
    Chen, Wenzhi
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2023, 22
  • [37] Anti-HER2 antibody therapy using gene-transduced adipocytes for HER2-positive breast cancer
    Masuda, Takahito
    Fujimoto, Hiroshi
    Teranaka, Ryotaro
    Kuroda, Masayuki
    Aoyagi, Yasuyuki
    Nagashima, Takeshi
    Sangai, Takafumi
    Takada, Mamoru
    Nakagawa, Ayako
    Kubota, Yoshitaka
    Yokote, Koutaro
    Ohtsuka, Masayuki
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (03) : 625 - 634
  • [38] MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy
    van Ramshorst, Mette S.
    Loo, Claudette E.
    Groen, Emilie J.
    Winter-Warnars, Gonneke H.
    Wesseling, Jelle
    van Duijnhoven, Frederieke
    Peeters, Marie-Jeanne T. Vrancken
    Sonke, Gabe S.
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 164 (01) : 99 - 106
  • [39] Role of innate and adaptive immunity in the efficacy of anti-HER2 monoclonal antibodies for HER2-positive breast cancer
    Musolino, Antonino
    Boggiani, Daniela
    Pellegrino, Benedetta
    Zanoni, Daniele
    Sikokis, Angelica
    Missale, Gabriele
    Silini, Enrico Maria
    Maglietta, Giuseppe
    Frassoldati, Antonio
    Michiara, Maria
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2020, 149
  • [40] HER2 and BARD1 Polymorphisms in Early HER2-Positive Breast Cancer Patients: Relationship with Response to Neoadjuvant Anti-HER2 Treatment
    Novillo, Apolonia
    Gaibar, Maria
    Romero-Lorca, Alicia
    Malon, Diego
    Anton, Beatriz
    Moreno, Amalia
    Fernandez-Santander, Ana
    CANCERS, 2023, 15 (03)
12345